Regulatory - EBC46 Research Hub (Page 2)

FDA government building representing drug approval regulatory pathway for oncology research

EBC-46

Stelfonta's FDA Approval: What It Means for Human Oncology Research

The FDA's full approval of Stelfonta validated tigilanol tiglate's PKC-activation mechanism for the first time, creating regulatory precedent that directly accelerates human oncology trials.

Government building columns representing regulatory authority and drug approval processes

EBC-46

Compassionate Use Pathways: How EBC-46 Could Reach Patients Before Full Approval

Regulatory frameworks for compassionate use and expanded access could allow tigilanol tiglate to reach patients with unmet needs well before Phase III completion.

FDA regulatory office documents representing Breakthrough Therapy Designation approval process

EBC-46

Breakthrough Therapy Designation: Could Tigilanol Tiglate Qualify and What Would It Mean?

Breakthrough Therapy Designation compresses development timelines dramatically. Here's how tigilanol tiglate stacks up against the FDA's criteria — and what qualifying would mean for patients.

Scales of justice in a modern government building symbolising regulatory oversight

EBC-46

Intratumoral Drug Approvals: The Unique Regulatory Challenges Facing EBC-46

Intratumoral drugs like tigilanol tiglate must satisfy regulatory requirements that conventional systemic cancer therapies were never designed to address — from injection site assessment to lesion-level endpoints.

European parliament building symbolising international regulatory frameworks for drug approval

EBC-46

EMA PRIME Designation: How Europe's Priority Medicines Programme Could Fast-Track EBC-46

The EMA's PRIME programme offers accelerated assessment and early dialogue for promising cancer therapies. Here is what that pathway could mean for tigilanol tiglate.

Medical regulatory documents and stethoscope representing FDA expanded access pathways for cancer drugs

EBC-46

Compassionate Use and Expanded Access: What They Mean for Tigilanol Tiglate Patients

Before a drug achieves full approval, compassionate use and expanded access programmes can provide a legal pathway for patients who have no other options. Here's how they apply to tigilanol tiglate.

Government regulatory building symbolising FDA and EMA drug approval pathways

EBC-46

Compassionate Use Pathways for Tigilanol Tiglate: How Patients Access Unapproved Cancer Drugs

Compassionate use and expanded access programmes could allow cancer patients to receive tigilanol tiglate before formal Phase III approval — here is how the regulatory framework works.

Medical regulatory documents and FDA approval paperwork on a clinical desk

EBC-46

Stelfonta's FDA Approval: What the Regulatory Pathway Tells Us About EBC-46's Future

Stelfonta became the first tigilanol tiglate product approved by the FDA. Understanding its regulatory journey maps the path EBC-46 must follow for human approval.

Pharmaceutical laboratory drug development research representing FDA orphan drug designation process

EBC-46

Orphan Drug Designation and EBC-46: What It Means for Patients with Rare Cancers

EBC-46 has received Orphan Drug Designation from the FDA for specific rare cancers. Here's what that regulatory milestone actually means — and why it matters for patients.

See all